Back Back
Cell No. : Cell Name
RCB2292 : ACC-MESO-1  update : 2023/10/16
CommentHuman malignant pleural mesothelioma cell line.
Comment from the depositor
Terms and conditionsIn publishing research results obtained by the use of the BIOLOGICAL RESOURCE, a citation of the literature ref. (Cancer Sci 2006;97:387-394) designated by the DEPOSITOR is required.
Order Form Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (
Basic information Depositor Sekido, Yoshitaka
Originator Hida, Toyoaki
Year of deposit 2006
Animal _human < Mammals
Genus Homo
Species sapiens
Race Japanese
Gender Female
Age at sampling 61 years
Tissue malignant pleural mesothelioma, pleural fluid
Disease name malignant pleural mesothelioma
Classification cancer
Lifespan infinite
Morphology fibroblast-like
Cellosaurus(Expasy) CVCL_5113
deposit info
lot info
Medium Medium List
Culture type Adherent cells
Culture medium RPMI1640 + 10% FBS
Antibiotics Free
Passage method 0.25% Trypsin or (0.05% Trypsin + 0.53mM EDTA) or (0.25% Trypsin + 0.53mM EDTA)
Culture information Passage ratio 1 : 8 split
SC frequency Subculture : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
Isozyme LD, NP
STR(human) OK
deposit info
lot info
Reference information Reference 3
User's Publication 52

To topTop
16027  Matsushita A, Sato T, Mukai S, Fujishita T, Mishiro-Sato E, Okuda M, Aoki M, Hasegawa Y, Sekido Y.  TAZ activation by Hippo pathway dysregulation induces cytokine gene expression and promotes mesothelial cell transformation  Oncogene  2018  38(11):1966-1978  PubMed ID: 30401981   DOI: 10.1038/s41388-018-0417-7
16469  Tanaka I, Osada H, Fujii M, Fukatsu A, Hida T, Horio Y, Kondo Y, Sato A, Hasegawa Y, Tsujimura T, Sekido Y.  LIM-domain protein AJUBA suppresses malignant mesothelioma cell proliferation via Hippo signaling cascade  Oncogene  2015  34(1):73-83  PubMed ID: 24336325   DOI: 10.1038/onc.2013.528
3337  Usami, Noriyasu, Fukui, Takayuki, Kondo, Masashi, Taniguchi, Tetsuo, Yokoyama, Toshihiko, Mori, Shoichi, Yokoi, Kohei, Horio, Yoshitsugu, Shimokata, Kaoru, Sekido, Yoshitaka, Hida, Toyoaki  Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients.  Cancer Sci  2006  97:387-94  PubMed ID: 16630136   DOI: 10.1111/j.1349-7006.2006.00184.x

To topTop
User's Publication
19954  Okamura K, Inoue H, Tanaka K, Ikematsu Y, Furukawa R, Ota K, Yoneshima Y, Iwama E, Okamoto I.  Immunostimulatory oncolytic activity of coxsackievirus A11 in human malignant pleural mesothelioma  Cancer Sci  2023  114(3):1095-1107  PubMed ID: 36369966   DOI: 10.1111/cas.15645
21058  Yang H, Gao Y, Xu D, Xu K, Liang SQ, Yang Z, Scherz A, Hall SRR, Forster S, Berezowska S, Yao F, Ochsenbein AF, Marti TM, Kocher GJ, Schmid RA, Dorn P, Peng RW.  MEK1 drives oncogenic signaling and interacts with PARP1 for genomic and metabolic homeostasis in malignant pleural mesothelioma.  Cell Death Discov  2023  9(1):55  PubMed ID: 36765038   DOI: 10.1038/s41420-023-01307-2
21089  Sakura K, Sasai M, Funaki S, Shintani Y, Okumura M, Kaneda Y.  Add-On Effect of Hemagglutinating Virus of Japan Envelope Combined with Chemotherapy or Immune Checkpoint Inhibitor against Malignant Pleural Mesothelioma: An In Vivo Study.  Cancers (Basel)  2023  15(3)  PubMed ID: 36765886   DOI: 10.3390/cancers15030929
21383  Endo I, Amatya VJ, Kushitani K, Kambara T, Nakagiri T, Aoe K, Takeshima Y.  FOXM1 Promotes Mesothelioma Cell Migration and Invasion via Activation of SMAD Signaling.  Anticancer Res  2023  43(9):3961-3968  PubMed ID: 37648326   DOI: 10.21873/anticanres.16583
21461  Nakagiri T, Amatya VJ, Kushitani K, Kambara T, Aoe K, Endo I, Miyata Y, Okada M, Takeshima Y.  SPARC Is a Novel Positive Immunohistochemical Marker of Epithelioid Mesothelioma to Differentiate It From Lung Adenocarcinoma and/or Squamous Cell Carcinoma.  Am J Surg Pathol  2023    PubMed ID: 37899530   DOI: 10.1097/PAS.0000000000002147
17557  Tomita R, Nishijo N, Hayama T, Fujioka T.  Discrimination of Malignant Pleural Mesothelioma Cell Lines Using Amino Acid Metabolomics with HPLC  Biol Pharm Bull  2022  45(6):724-729.  PubMed ID: 35650101   DOI: 10.1248/bpb.b21-00972
17590  Hagiyama M, Mimae T, Wada A, Takeuchi F, Yoneshige A, Inoue T, Kotoku N, Hamada H, Sekido Y, Okada M, Ito A.  Possible Therapeutic Utility of anti-Cell Adhesion Molecule 1 Antibodies for Malignant Pleural Mesothelioma  Front Cell Dev Biol  2022  10:945007  PubMed ID: 35903548   DOI: 10.3389/fcell.2022.945007
17671  Endo I, Amatya VJ, Kushitani K, Kambara T, Nakagiri T, Fujii Y, Takeshima Y.  Insulin-Like Growth Factor 2 mRNA Binding Protein 3 Promotes Cell Proliferation of Malignant Mesothelioma Cells by Downregulating p27Kip1  Front Oncol  2022  11:795467  PubMed ID: 35127504   DOI: 10.3389/fonc.2021.795467
20462  Fujii Y, Amatya VJ, Kushitani K, Suzuki R, Kai Y, Kambara T, Takeshima Y.  Downregulation of lncRNA PVT1 inhibits proliferation and migration of mesothelioma cells by targeting FOXM1.  Oncol Rep  2022  47(2)  PubMed ID: 34859258   DOI: 10.3892/or.2021.8238
20801  Hasegawa M, Hanamatsu Y, Saigo C, Kito Y, Takeuchi T.  Tumor suppressor effect of an antibody on xenotransplanted sarcomatoid mesothelioma cells.  Thorac Cancer  2022    PubMed ID: 35916358   DOI: 10.1111/1759-7714.14591
20093  Yang H, Hall SRR, Sun B, Zhao L, Gao Y, Schmid RA, Tan ST, Peng RW, Yao F.  NF2 and Canonical Hippo-YAP Pathway Define Distinct Tumor Subsets Characterized by Different Immune Deficiency and Treatment Implications in Human Pleural Mesothelioma.  Cancers (Basel)  2021  13(7)  PubMed ID: 33805359   DOI: 10.3390/cancers13071561
20510  Takasaka M, Kobayashi S, Usui Y, Haniu H, Tsuruoka S, Aoki K, Saito N.  Biokinetic Evaluation of Contrast Media Loaded Carbon Nanotubes Using a Radiographic Device.  Toxics  2021  9(12)  PubMed ID: 34941765   DOI: 10.3390/toxics9120331
20560  Abukar A, Wipplinger M, Hariharan A, Sun S, Ronner M, Sculco M, Okonska A, Kresoja-Rakic J, Rehrauer H, Qi W, Beusechem VWV, Felley-Bosco E.  Double-Stranded RNA Structural Elements Holding the Key to Translational Regulation in Cancer: The Case of Editing in RNA-Binding Motif Protein 8A.  Cells  2021  10(12)  PubMed ID: 34944051   DOI: 10.3390/cells10123543
16120  Kanayama M, Oyama R, Mori M, Taira A, Shinohara S, Kuwata T, Takenaka M, Yoneda K, Kuroda K, Ohnaga T, Kato Y, Tanaka F.  Novel circulating tumor cell-detection chip combining conventional podoplanin and EGFR antibodies for all histological malignant pleural mesothelioma  Oncol Lett  2021  22(1):522  PubMed ID: 34025789   DOI: 10.3892/ol.2021.12783
6938  Okonska A, Bühler S, Rao V, Ronner M, Blijlevens M, van der Meulen-Muileman IH, de Menezes RX, Wipplinger M, Oehl K, Smit EF, Weder W, Stahel RA, Penengo L, van Beusechem VW, Felley-Bosco E.  Functional genomic screen in mesothelioma reveals that loss of function of BRCA1-associated-protein-1 induces chemoresistance to ribonucleotide reductase inhibition.  Mol Cancer Ther  2020  19(2):552-563  PubMed ID: 31619462   DOI: 10.1158/1535-7163.MCT-19-0356
12125  Fujii T, Itami H, Uchiyama T, Morita K, Nakai T, Hatakeyama K, Sugimoto A, Shimada K, Tsuji S, Ohbayashi C.  HEG1-responsive microRNA-23b regulates cell proliferation in malignant mesothelioma cells.  Biochem. Biophys. Res. Commun.  2020    PubMed ID: 32284171   DOI: 10.1016/j.bbrc.2020.03.172
13171  Yang H, Xu D, Yang Z, Yao F, Zhao H, Schmid RA, Peng RW.  Systematic Analysis of Aberrant Biochemical Networks and Potential Drug Vulnerabilities Induced by Tumor Suppressor Loss in Malignant Pleural Mesothelioma.  Cancers (Basel)  2020    PubMed ID: 32824422   DOI: 10.3390/cancers12082310
13236  Jotatsu T, Izumi H, Morimoto Y, Yatera K.  Selection of microRNAs in extracellular vesicles for diagnosis of malignant pleural mesothelioma by in vitro analysis.  Oncol Rep  2020    PubMed ID: 33000251   DOI: 10.3892/or.2020.7778
13275  Sakai K, Nishiuchi T, Tange S, Suzuki Y, Yano S, Terashima M, Suzuki T, Matsumoto K.  Proteasomal degradation of polycomb-group protein CBX6 confers MMP-2 expression essential for mesothelioma invasion.  Sci Rep  2020    PubMed ID: 33028834   DOI: 10.1038/s41598-020-72448-y
13551  Han B, Lee-Okada HC, Ishimine M, Orita H, Nishikawa K, Takagaki T, Kajino K, Yokomizo T, Hino O, Kobayashi T.  Combined use of irinotecan and p53 activator enhances growth inhibition of mesothelioma cells  FEBS Open Bio  2020  10(11):2375-2387  PubMed ID: 32961616   DOI: 10.1002/2211-5463.12985
13608  Kuwata T, Yoneda K, Mori M, Kanayama M, Kuroda K, Kaneko MK, Kato Y, Tanaka F.  Detection of Circulating Tumor Cells (CTCs) in Malignant Pleural Mesothelioma (MPM) with the "Universal" CTC-Chip and An Anti-Podoplanin Antibody NZ-1.2  Cells  2020  9(4):888  PubMed ID: 32260559   DOI: 10.3390/cells9040888
14504  Suzuki R, Amatya VJ, Kushitani K, Kai Y, Kambara T, Fujii Y, Takeshima Y.  Inhibition of miR-18a-3p reduces proliferation of mesothelioma cells and sensitizes them to cisplatin  Oncol Lett  2020  19(6):4161-4168  PubMed ID: 32382354   DOI: 10.3892/ol.2020.11504
10679  Yoneda K, Chikaishi Y, Kuwata T, Ohnaga T, Tanaka F.  Capture of mesothelioma cells with 'universal' CTC-chip.  Oncol Lett  2018  15:2635-2640  PubMed ID: 29434985   DOI: 10.3892/ol.2017.7619
11150  Ohno Y, Shingyoku S, Miyake S, Tanaka A, Fudesaka S, Shimizu Y, Yoshifuji A, Yamawaki Y, Yoshida S, Tanaka S, Sakura K, Tanaka T.  Differential regulation of the sphere formation and maintenance of cancer-initiating cells of malignant mesothelioma via CD44 and ALK4 signaling pathways.  Oncogene  2018  37(49):6357-6367  PubMed ID: 30061637   DOI: 10.1038/s41388-018-0405-y
11207  Okamoto T, Yamazaki H, Hatano R, Yamada T, Kaneko Y, Xu CW, Dang NH, Ohnuma K, Morimoto C.  Targeting CD26 suppresses proliferation of malignant mesothelioma cell via downmodulation of ubiquitin-specific protease 22.  Biochem. Biophys. Res. Commun.  2018    PubMed ID: 30197002   DOI: 10.1016/j.bbrc.2018.08.193
11107  Xu D, Liang SQ, Yang H, Luthi U, Riether C, Berezowska S, Marti TM, Hall SRR, Bruggmann R, Kocher GJ, Schmid RA, Peng RW.  Increased sensitivity to apoptosis upon endoplasmic reticulum stress-induced activation of the unfolded protein response in chemotherapy-resistant malignant pleural mesothelioma.  Br. J. Cancer  2018  119(1):65-75  PubMed ID: 29921948   DOI: 10.1038/s41416-018-0145-3
11217  Matsuura R, Kaji H, Tomioka A, Sato T, Narimatsu H, Moriwaki Y, Misawa H, Imai K, Tsuji S.  Identification of mesothelioma-specific sialylated epitope recognized with monoclonal antibody SKM9-2 in a mucin-like membrane protein HEG1.  Sci Rep  2018    PubMed ID: 30250045   DOI: 10.1038/s41598-018-32534-8
4469  Suzuki R, Amatya VJ, Kushitani K, Kai Y, Kambara T, Takeshima Y.  miR-182 and miR-183 Promote Cell Proliferation and Invasion by Targeting FOXO1 in Mesothelioma.  Front Oncol  2018  8:446  PubMed ID: 30406026   DOI: 10.3389/fonc.2018.00446
7034  Tsuji S, Washimi K, Kageyama T, Yamashita M, Yoshihara M, Matsuura R, Yokose T, Kameda Y, Hayashi H, Morohoshi T, Tsuura Y, Yusa T, Sato T, Togayachi A, Narimatsu H, Nagasaki T, Nakamoto K, Moriwaki Y, Misawa H, Hiroshima K, Miyagi Y, Imai K.  HEG1 is a novel mucin-like membrane protein that serves as a diagnostic and therapeutic target for malignant mesothelioma.  Sci Rep  2017  7:45768  PubMed ID: 28361969   DOI: 10.1038/srep45768
14252  Maki T, Ikeda H, Kuroda A, Kyogoku N, Yamamura Y, Tabata Y, Abiko T, Tsuchikawa T, Hida Y, Shichinohe T, Tanaka E, Kaga K, Hatanaka K, Matsuno Y, Imai N, Hirano S.  Differential detection of cytoplasmic Wilms tumor 1 expression by immunohistochemistry, western blotting and mRNA quantification  Int J Oncol  2017  50(1):129-140.  PubMed ID: 27922671   DOI: 10.3892/ijo.2016.3786
14253  Satoh T, Tatsuta T, Sugawara S, Hara A, Hosono M.  Synergistic anti-tumor effect of bullfrog sialic acid-binding lectin and pemetrexed in malignant mesothelioma  Oncotarget  2017  8(26):42466-42477  PubMed ID: 28476017   DOI: 10.18632/oncotarget.17198
14487  Mawas AS, Amatya VJ, Suzuki R, Kushitani K, Mohi El-Din MM, Takeshima Y.  PIM1 knockdown inhibits cell proliferation and invasion of mesothelioma cells  Int J Oncol  2017  50(3):1029-1034  PubMed ID: 28197633   DOI: 10.3892/ijo.2017.3863
9731  Mizutani N, Abe M, Matsuoka S, Kajino K, Wakiya M, Ohtsuji N, Hatano R, Morimoto C, Hino O.  Establishment of anti-mesothelioma monoclonal antibodies.  BMC Res Notes  2016  9:324  PubMed ID: 27342200   DOI: 10.1186/s13104-016-2128-x
12632  Amatya VJ, Mawas AS, Kushitani K, Mohi El-Din MM, Takeshima Y.  Differential microRNA expression profiling of mesothelioma and expression analysis of miR-1 and miR-214 in mesothelioma  Int J Oncol  2016  48(4):1599-607  PubMed ID: 26820394   DOI: 10.3892/ijo.2016.3358
12672  Seki Y, Fujiwara Y, Kohno T, Takai E, Sunami K, Goto Y, Horinouchi H, Kanda S, Nokihara H, Watanabe S, Ichikawa H, Yamamoto N, Kuwano K, Ohe Y.  Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors  Oncologist  2016  21(2):156-64  PubMed ID: 26768482   DOI: 10.1634/theoncologist.2015-0288
12680  Kushitani K, Amatya VJ, Mawas AS, Miyata Y, Okada M, Takeshima Y.  Use of Anti-Noxa Antibody for Differential Diagnosis between Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia  Pathobiology  2016  83(1):33-40  PubMed ID: 26735863   DOI: 10.1159/000442092
12937  Hida T, Hamasaki M, Matsumoto S, Sato A, Tsujimura T, Kawahara K, Iwasaki A, Okamoto T, Oda Y, Honda H, Nabeshima K.  BAP1 immunohistochemistry and p16 FISH results in combination provide higher confidence in malignant pleural mesothelioma diagnosis: ROC analysis of the two tests  Pathol Int  2016  66(10):563-570.  PubMed ID: 27614970   DOI: 10.1111/pin.12453
5349  Maruyama K, Haniu H, Saito N, Matsuda Y, Tsukahara T, Kobayashi S, Tanaka M, Aoki K, Takanashi S, Okamoto M, Kato H.  Endocytosis of Multiwalled Carbon Nanotubes in Bronchial Epithelial and Mesothelial Cells  Biomed Res Int  2015  2015:793186  PubMed ID: 26090445   DOI: 10.1155/2015/793186
3916  Okabe S, Okamoto T, Zhao CM, Chen D, Matsui H.  Acetic acid induces cell death: an in vitro study using normal rat gastric mucosal cell line and rat and human gastric cancer and mesothelioma cell lines.  J Gastroenterol Hepatol  2014  29 Suppl 4:65-9  PubMed ID: 25521736   DOI: 10.1111/jgh.12775
9149  Yoshikane Yamauchi, Yotaro Izumi, Keisuke Asakura, Yuichiro Hayashi, Hiroaki Nomori  Curcumin Induces Autophagy in ACC-MESO-1 Cells  Phytother Res  2012  26 (12), 1779-83  PubMed ID: 22388865   DOI: 10.1002/ptr.4645
7592  Haniu H, Saito N, Matsuda Y, Kim YA, Park KC, Tsukahara T, Usui Y, Aoki K, Shimizu M, Ogihara N, Hara K, Takanashi S, Okamoto M, Ishigaki N, Nakamura K, Kato H.  Effect of dispersants of multi-walled carbon nanotubes on cellular uptake and biological responses.  Int J Nanomedicine  2011  6:3295-307  PubMed ID: 22228997   DOI: 10.2147/IJN.S26573
7727  Asakura K, Izumi Y, Yamamoto M, Yamauchi Y, Kawai K, Serizawa A, Mizushima T, Ohmura M, Kawamura M, Wakui M, Adachi T, Nakamura M, Suematsu M, Nomori H.  The cytostatic effects of lovastatin on ACC-MESO-1 cells.  J. Surg. Res.  2011  170:e197-209  PubMed ID: 21816418   DOI: 10.1016/j.jss.2011.06.037
7784  Yamauchi Y, Izumi Y, Asakura K, Fukutomi T, Serizawa A, Kawai K, Wakui M, Suematsu M, Nomori H.  Lovastatin and valproic acid additively attenuate cell invasion in ACC-MESO-1 cells.  Biochem. Biophys. Res. Commun.  2011  410:328-32  PubMed ID: 21672521   DOI: 10.1016/j.bbrc.2011.05.149
8088  Iwahori K, Serada S, Fujimoto M, Nomura S, Osaki T, Lee CM, Mizuguchi H, Takahashi T, Ripley B, Okumura M, Kawase I, Kishimoto T, Naka T.  Overexpression of SOCS3 exhibits preclinical antitumor activity against malignant pleural mesothelioma.  Int. J. Cancer  2011  129:1005-17  PubMed ID: 20949562   DOI: 10.1002/ijc.25716
8199  Hasegawa S, Koshikawa-Yano M, Saito S, Morokoshi Y, Furukawa T, Aoki I, Saga T.  Molecular imaging of mesothelioma by detection of manganese-superoxide dismutase activity using manganese-enhanced magnetic resonance imaging.  Int. J. Cancer  2011  128:2138-46  PubMed ID: 20617513   DOI: 10.1002/ijc.25547
5413  Haniu H, Saito N, Matsuda Y, Kim YA, Park KC, Tsukahara T, Usui Y, Aoki K, Shimizu M, Ogihara N, Hara K, Takanashi S, Okamoto M, Ishigaki N, Nakamura K, Kato H.  Elucidation mechanism of different biological responses to multi-walled carbon nanotubes using four cell lines.  Int J Nanomedicine  2011  6:3487-97  PubMed ID: 22267932   DOI: 10.2147/IJN.S26689
16309  Haniu H, Tsukahara T, Matsuda Y, Usui Y, Aoki K, Shimizu M, Ogihara N, Hara K, Takanashi S, Okamoto M, Ishigaki N, Nakamura K, Kato H, Saito N.  DJ-1 as a potential biomarker for the development of biocompatible multiwalled carbon nanotubes  Int J Nanomedicine  2011  6:2689-95  PubMed ID: 22114499   DOI: 10.2147/IJN.S25471
8186  Tsuji S, Tsuura Y, Morohoshi T, Shinohara T, Oshita F, Yamada K, Kameda Y, Ohtsu T, Nakamura Y, Miyagi Y.  Secretion of intelectin-1 from malignant pleural mesothelioma into pleural effusion.  Br. J. Cancer  2010  103:517-23  PubMed ID: 20628387   DOI: 10.1038/sj.bjc.6605786
8379  Suzuki Y, Sakai K, Ueki J, Xu Q, Nakamura T, Shimada H, Nakamura T, Matsumoto K.  Inhibition of Met/HGF receptor and angiogenesis by NK4 leads to suppression of tumor growth and migration in malignant pleural mesothelioma.  Int. J. Cancer  2010  127:1948-57  PubMed ID: 20104519   DOI: 10.1002/ijc.25197
18472  Nabeta M, Abe Y, Kagawa L, Haraguchi R, Kito K, Ueda N, Sugita A, Yokoyama M, Kusanagi Y, Ito M.  Identification of anti-α-enolase autoantibody as a novel serum marker for endometriosis  Proteomics Clin Appl  2009  3(10):1201-10  PubMed ID: 21136944   DOI: 10.1002/prca.200900055
13735  Ito A, Hagiyama M, Mimura T, Matsumoto M, Wakayama T, Iseki S, Yokozaki H, Okada M.  Expression of cell adhesion molecule 1 in malignant pleural mesothelioma as a cause of efficient adhesion and growth on mesothelium  Lab Invest  2008  88(5):504-14  PubMed ID: 18332875   DOI: 10.1038/labinvest.2008.15
16153  Ishida T, Obata Y, Ohara N, Matsushita H, Sato S, Uenaka A, Saika T, Miyamura T, Chayama K, Nakamura Y, Wada H, Yamashita T, Morishima T, Old LJ, Nakayama E.  Identification of the HERV-K gag antigen in prostate cancer by SEREX using autologous patient serum and its immunogenicity  Cancer Immun  2008  8:15.  PubMed ID: 19006261  

Back Back Return Top Page